Amgen (AMGN) Stock Analysis

Amgen (AMGN) Symbol Information

AMGN trades on NASDAQ. The panel below summarizes the current symbol — price, exchange and identifying details — as a quick reference before reviewing deeper fundamentals and charts.

Market information shown here may update dynamically throughout the trading session. Verify any material figure through Amgen’s official filings before relying on it.

AMGN Advanced Stock Chart

The interactive chart below displays AMGN price and volume history across multiple time intervals, from intraday to multi-year views. AMGN’s share price has historically reacted closely to clinical trial readouts — including for pipeline candidates such as MariTide — regulatory decisions, biosimilar competition affecting legacy products such as Enbrel, and U.S. drug-pricing policy developments; price history is one input among several and should be considered alongside fundamentals, not in isolation.

Chart patterns are not guarantees of future performance. Price movements may reflect quarterly product-sales results across Amgen’s therapeutic portfolio, Phase 3 clinical data for MariTide, FDA regulatory actions, Medicare Drug Price Negotiation Program developments affecting products such as Otezla, or broader sentiment toward large-cap biopharmaceutical and obesity-therapeutics stocks.

AMGN Financial Statements and Fundamentals

Key figures worth examining for Amgen include total product sales, the mix between growth products (Repatha, Evenity, Uplizna and Tezspire) and legacy or biosimilar-exposed products (Enbrel and Neulasta), gross and operating margin, research and development spend directed at late-stage pipeline candidates such as MariTide, and capital-return activity. Amgen pays a quarterly cash dividend that has been increased in each of the past several years and also repurchases shares, while carrying meaningful interest-bearing debt, including financing associated with its 2023 acquisition of Horizon Therapeutics.

Financial panels should be read across multiple reporting periods rather than a single quarter, and checked against Amgen’s official filings via its SEC filings page.

AMGN Company Profile and Business Model

Amgen operates as a single reportable segment — human therapeutics — spanning core therapeutic areas that include oncology, inflammation, bone health, cardiovascular disease, nephrology and rare disease. Its commercial portfolio includes long-established medicines such as Enbrel (inflammatory disease), Prolia and Evenity (bone health), Repatha (cholesterol management) and Otezla (psoriasis and psoriatic arthritis), alongside newer growth drivers including Uplizna, Tezspire, Tepezza and Blincyto, a biosimilars business (including Amjevita/Amgevita, Mvasi, Wezlana and Pavblu), and a late-stage pipeline led by the obesity and type 2 diabetes candidate MariTide (maridebart cafraglutide), currently in Phase 3 development.

Amgen’s competitive position rests on its scale in biologics manufacturing, an established commercial infrastructure across inflammation, bone health, cardiovascular disease and oncology, and a broadening biosimilars business. Principal competitors include large diversified biopharmaceutical companies such as Pfizer, AbbVie, Johnson & Johnson, Novartis, Roche, Bristol Myers Squibb and Eli Lilly, with more targeted competition from Regeneron, Novo Nordisk and Eli Lilly in the fast-growing obesity and metabolic-disease category where MariTide would compete against established GLP-1 therapies if approved.

AMGN Technical Analysis

This widget summarizes technical indicators — moving averages, oscillators and overall signal counts — for AMGN across selected timeframes.

Technical signals change as new data arrives and should not be treated as a recommendation. Consider them together with fundamentals, valuation, clinical trial catalysts and Amgen’s exposure to biosimilar competition and U.S. drug-pricing policy.

AMGN Historical Stock-Price Overview

The overview below covers AMGN price and percentage change across several date ranges, with volume and moving-average context. AMGN’s long-term stock history reflects its evolution from a pioneering biotechnology innovator into a diversified biopharmaceutical company, shaped by patent expirations and biosimilar competition affecting products such as Enbrel and Neulasta, the 2023 acquisition of Horizon Therapeutics (adding Tepezza and Uplizna), and more recently investor attention to Phase 3 development of MariTide in the obesity market — best interpreted alongside those business developments rather than price movement alone.

Historical performance does not guarantee future results and reflects a specific past period only.

AMGN Shariah Compliance Snapshot

The snapshot below reflects third-party Shariah screening for AMGN based on AAOIFI-derived methodology. Screening results change as market capitalization, debt, cash and non-permissible income change — treat this as a starting reference, not a permanent certification.

Latest AMGN News

The feed below may include dynamically updated market stories related to AMGN.

Distinguish between official Amgen announcements, SEC filings, earnings releases, analyst commentary and general media coverage. Verify material news through Amgen’s investor relations page and official filings.